GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » EBITDA Margin %

Myrexis (Myrexis) EBITDA Margin % : 0.00% (As of Jun. 2013)


View and export this data going back to 2013. Start your Free Trial

What is Myrexis EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Myrexis's EBITDA for the three months ended in Jun. 2013 was $-0.15 Mil. Myrexis's Revenue for the three months ended in Jun. 2013 was $0.00 Mil. Therefore, Myrexis's EBITDA margin for the quarter that ended in Jun. 2013 was 0.00%.


Myrexis EBITDA Margin % Historical Data

The historical data trend for Myrexis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis EBITDA Margin % Chart

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
EBITDA Margin %
Get a 7-Day Free Trial -1,013.23 -51,965.56 -20,967.03 - -

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Myrexis's EBITDA Margin %

For the Shell Companies subindustry, Myrexis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myrexis's EBITDA Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Myrexis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Myrexis's EBITDA Margin % falls into.



Myrexis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Myrexis's EBITDA Margin % for the fiscal year that ended in Jun. 2013 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2013 )/Revenue (A: Jun. 2013 )
=-11.604/0
= %

Myrexis's EBITDA Margin % for the quarter that ended in Jun. 2013 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2013 )/Revenue (Q: Jun. 2013 )
=-0.153/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myrexis  (OTCPK:MYRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Myrexis EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Myrexis's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myrexis (Myrexis) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.
Executives
Xstelos Corp. 10 percent owner 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe director 1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper director 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman director, officer: Chairman, President and CEO 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle director 320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska director, officer: Chief Operating Officer 749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer director, officer: President and CEO C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden director, officer: President and CEO 320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie officer: Chief Operating Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines